Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BNZ-1
BNZ132-1-40 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BNZ-1 | EXPERIMENTAL | IV PEGylated BNZ132-1-40 |
| Name | Type | Description |
|---|---|---|
| BNZ132-1-40 | DRUG | Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15 |
Inclusion Criteria: * Willing and able to consent and participate in the study. * Agrees not to receive any other investigational product or therapy while participating in this study. * Must be: * Currently using two forms of effective birth control (one of which is a barrier method) for the dur...
Top 20 of 60 competitors
BNZ132-1-40 is an investigational small molecule developed by Equillium, Inc. (ticker EQ) for LGL Leukemia, a rare blood cancer. It has completed a Phase 1 dose-ranging study. It is not approved and remains in clinical development.
BNZ132-1-40 is being studied for the treatment of LGL Leukemia, a rare hematologic malignancy. Its only clinical trial also enrolled patients with refractory CTCL. The drug is investigational and has not been approved for any indication.
BNZ132-1-40 is developed by Equillium, Inc., a biopharmaceutical company whose ticker symbol is EQ. Equillium is the sponsor of the clinical program evaluating the drug in LGL Leukemia and refractory CTCL.
BNZ132-1-40 is in Phase 1 development. Its single trial, a dose-ranging study, has been completed. The drug is investigational and has not received FDA approval for LGL Leukemia or any other condition.
BNZ132-1-40 has been evaluated in one clinical trial, NCT03239392, titled A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL. The Phase 1 trial enrolled 50 participants in the United States and is now completed.